Physician profile
Olena Dotsenko
NPI 1326228669
$1,854.77
in general payments reported to CMS, 2019-2025
25 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $120 · 2021: $362 · 2022: $334 · 2023: $549 · 2024: $139 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $896.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $528.04 | 2019-2024 | Verquvo, Lagevrio |
| Boston Scientific Corporation | $297.13 | 2021-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, General - Therapies |
| Novartis Pharmaceuticals Corporation | $174.51 | 2021-2025 | Leqvio |
| Abbott Laboratories | $85.03 | 2021 | |
| Bridgebio Pharma, INC. | $77.96 | 2025 | Attruby |
| Amarin Pharma, INC. | $72.14 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.74 | 2020-2022 | |
| Pfizer INC. | $65.48 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $62.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $50.57 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.05 | 2019 | |
| Amgen INC. | $42.03 | 2019-2025 | Repatha |
| Nestle Healthcare Nutrition INC. | $35.61 | 2022-2023 | |
| Chiesi USA, INC. | $32.22 | 2022 | |
| Itamar Medical INC | $29.69 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.52 | 2020-2024 | Eliquis |
| Amneal Pharmaceuticals LLC | $21.56 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.96 | 2023 | Inpefa |
| Abbvie INC. | $19.35 | 2023 | Ubrelvy |
| Abiomed | $18.92 | 2025 | |
| Scpharmaceuticals INC. | $17.28 | 2024 | |
| Allergan, INC. | $17.14 | 2019 | |
| Medtronic, INC. | $14.97 | 2023 | Onyx Frontier |
| Astrazeneca Pharmaceuticals LP | $13.92 | 2023 | Brilinta |
| Gilead Sciences, INC. | $12.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olena Dotsenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.